Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interleukin, OralDNA take tooth loss risk test to US

This article was originally published in Clinica

Executive Summary

Interleukin Genetics is set to make its PST genetic test for risk of periodontal disease available in the US through diagnostic firm OralDNA Labs. The two companies have entered a non-exclusive marketing, sales and distribution agreement for the test that will see OralDNA pay Interleukin (Waltham, Massachusetts) a set fee for each individual test that is sold. OralDNA will be responsible for the marketing costs of the test, which is aimed at the $70-96bn US dental market. According to Brentwood, Tennessee-based OralDNA, the addition of the PST test to its portfolio will complement its existing products, including the MyPerioPath test for pathogenic bacteria in the gums, and benefit the US dental community. Specific financial details of the deal were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel